PharmaceuticalGhrelin receptor agonistGH secretagogue
Tabimorelin
Also known as NN703 · NNC 26-0703
Orally active ghrelin-receptor agonist studied for adult GH deficiency and as a GH secretagogue. Development was discontinued after chronic dosing showed liver enzyme elevations and CYP3A4 induction.
01 Overview
Tabimorelin (NN703) is a peptidomimetic GHSR-1a agonist that raises GH and IGF-1 after oral dosing. It was investigated for adult GH deficiency and as an anabolic secretagogue in the early 2000s.
Chronic administration produced elevations in liver transaminases and induction of CYP3A4, and development was ultimately abandoned. Its human data are limited to small early-phase studies, so its research base is modest.
02 Mechanism
Agonist at the ghrelin/GHSR-1a receptor promoting pituitary GH release; also crosses into peripheral tissues.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Investigational | 0.5–5 mg/kg/day | Oral | Doses used in discontinued early-phase studies; not approved. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Raised GH and IGF-1Increased GH and IGF-1 after oral dosing in short trials. | dose-dependent | Clinical | |
| Orally activeEffective by mouth, unlike injectable GHRP peptides, an advantage that motivated its development. | peptidomimetic | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Elevated liver enzymesTransaminase elevations on chronic dosing halted development. | Moderate | Common | Clinical | |
| Drug interactions via CYP3A4Induces CYP3A4, altering metabolism of co-administered drugs. | Moderate | Unknown | Clinical |
06 Legal status
United States
Never approved
Research compound; development discontinued. · as of Jan 2026
07 References
Tabimorelin (NN703), an orally active GH secretagogueEur J Endocrinol, 2004
08 Discussion0 comments
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.